European Journal of Health Economics

Papers
(The H4-Index of European Journal of Health Economics is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Education and medication use later in life and the role of intelligence103
Beyond 10-year lead-times in EQ-5D-5L: leveraging alternative lead-times in willingness-to-accept questions to capture preferences for worse-than-dead states and their implication54
Psychometric properties and general population reference values for PROMIS Global Health in Hungary38
The hidden cost of sophistication: economic complexity and obesity34
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries31
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial30
Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis24
Risk equalization and prevention23
Domain-specific discounting of health and money: implications for health technology assessment23
Pragmatic randomized controlled trial comparing a complex telemedicine-based intervention with usual care in patients with chronic conditions22
Economic value of non-professional care in Spain. An analysis of the last decade22
Prescription opioids and economic hardship in France20
Patient-level cost analysis of subfertility pathways in the Dutch healthcare system20
Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study20
Cost awareness among intensivists in their daily clinical practice: a prospective multicentre study19
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan19
Setting incentives right with long-term risk adjustment18
Nothing about us, without us? A reflection on and call for involving children in the process of valuing child health18
Replay to: Comparison of EQ-5D-5 L and EORTC QLU-C10D utilities in gastric cancer patients18
0.20442700386047